A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer

Phase Ii ◽

Phase Ii Study ◽

6118 POSTER Randomized Phase II Study of S-1, Oral Leucovorin, and Oxaliplatin Combination Therapy (SOL) Versus MFOLFOX6 in Patients With Untreated Metastatic Colorectal Cancer (mCRC)

European Journal of Cancer ◽

10.1016/s0959-8049(11)71763-4 ◽

2011 ◽

Vol 47 ◽

pp. S427-S428

Author(s):

H. Ojima ◽

K. Yamazaki ◽

H. Kuwano ◽

T. Otsuji ◽

T. Kato ◽

...

Keyword(s):

Colorectal Cancer ◽

Combination Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G

Annals of Oncology ◽

10.1093/annonc/mdy281.151 ◽

2018 ◽

Vol 29 ◽

pp. viii201

Author(s):

Y. Kito ◽

T. Yamada ◽

T. Matsumoto ◽

H. Yasui ◽

K. Murata ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

First Line Treatment

5-Fluorouracil Administered as a 48-Hour Chronomodulated Infusion in Combination with Leucovorin and Cisplatin: A Randomized Phase II Study in Metastatic Colorectal Cancer

Oncology ◽

10.1159/000055349 ◽

2001 ◽

Vol 61 (1) ◽

pp. 28-35 ◽

Cited By ~ 8

Author(s):

Alfredo Falcone ◽

Giacomo Allegrini ◽

Gianluca Masi ◽

Monica Lencioni ◽

Elisabetta Pfanner ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)

Medical Oncology ◽

10.1007/s12032-019-1254-4 ◽

2019 ◽

Vol 36 (6) ◽

Cited By ~ 1

Author(s):

Naoki Nagata ◽

Hiromichi Maeda ◽

Keiichiro Ishibashi ◽

Keiji Hirata ◽

Akitaka Makiyama ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Wild Type ◽

Open Label ◽

Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC).

10.1200/jco.2010.28.15_suppl.3531 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 3531-3531 ◽

Cited By ~ 4

Author(s):

D. A. Richards ◽

J. J. Nemunaitis ◽

S. J. Vukelja ◽

C. T. Hagenstad ◽

L. T. Campos ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Third Line

PEAK: A randomized phase II study to compare the efficacy of panitumumab plus mFOLFOX6 to bevacizumab plus mFOLFOX6 in patients (pts) with previously untreated, unresectable metastatic colorectal cancer (mCRC) expressing wild-type KRAS.

10.1200/jco.2010.28.15_suppl.tps189 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS189-TPS189

Author(s):

L. S. Schwartzberg ◽

V. J. Wagner

Keyword(s):

Colorectal Cancer ◽

Unresectable Metastatic Colorectal Cancer

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Randomized Phase Ii ◽

Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE).

10.1200/jco.2014.32.15_suppl.tps3662 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS3662-TPS3662

Author(s):

Kohei Shitara ◽

Kentaro Yamazaki ◽

Hiroyuki Uetake ◽

Takeshi Kato ◽

Eiji Oki ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Randomized Phase Ii ◽

Reverse Sequence ◽

Previously Treated

A randomized phase II study (B2151005) of the intravenous phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS metastatic colorectal cancer (mCRC).

10.1200/jco.2014.32.15_suppl.tps3649 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS3649-TPS3649 ◽

Cited By ~ 2

Author(s):

Josep Tabernero ◽

Nicoletta Brega ◽

Craig Davis ◽

Ashwin Gollerkeri ◽

Kristen Pierce ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Mtor Inhibitor ◽

Phase Ii Study ◽

Mammalian Target Of Rapamycin ◽

Target Of Rapamycin ◽

Wild Type ◽

Phosphatidylinositol 3 Kinase ◽

Persistent prevention of CIPN using calmangafodipir (PledOx): Results from a placebo-controlled randomized phase II study (PLIANT) in patients with metastatic colorectal cancer (mCRC).

10.1200/jco.2016.34.15_suppl.10018 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 10018-10018 ◽

Cited By ~ 2

Author(s):

Bengt Glimelius ◽

Nebojsa Manojlovic ◽

Per Pfeiffer ◽

Baadur Mosidze ◽

Galina Petrova Kurteva ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial

Clinical Colorectal Cancer ◽

10.1016/j.clcc.2018.03.001 ◽

2018 ◽

Vol 17 (3) ◽

pp. 231-239.e7 ◽

Cited By ~ 13

Author(s):

Derek J. Jonker ◽

Patricia A. Tang ◽

Hagen Kennecke ◽

Stephen A. Welch ◽

M. Christine Cripps ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Cancer Trials ◽

Group Trial